An Act Requiring Newborn Screening For Duchenne Muscular Dystrophy.
Summary
HB 6919 would expand Connecticut’s newborn screening program to require testing for Duchenne muscular dystrophy, with implementation set for July 1, 2027. The bill also updates the existing newborn screening statute to reflect that cytomegalovirus (CMV) will be added to the screening list on July 1, 2025, while preserving the Commissioner of Public Health’s authority to publish and manage the list of screened conditions. In practical terms, the measure adds Duchenne muscular dystrophy to the state’s standard panel of conditions identified through newborn screening.
The bill amends section 19a-55(c) of the general statutes, which governs the conditions included in Connecticut’s newborn screening program. By inserting Duchenne muscular dystrophy into the statute, the bill creates a specific legal mandate for the Department of Public Health to include that disorder in newborn screening beginning in 2027. It also aligns the statute with other conditions already required or authorized for screening, including a broad range of metabolic, endocrine, immune, and genetic disorders.
Impact
The bill would change Connecticut law by expressly requiring newborn screening for Duchenne muscular dystrophy and by updating the statutory list of conditions screened by the Department of Public Health. It affects newborns and their families, as well as hospitals, laboratories, and public health officials responsible for collecting, testing, and reporting screening results. The measure also reinforces the commissioner’s role in maintaining the screening panel and may require administrative, laboratory, and follow-up protocol updates before the effective dates.
Sentiment
The available voting record suggests broad support for the bill. It received joint favorable reports from the Public Health Committee, the Insurance and Real Estate Committee, and the Appropriations Committee, with strong majority votes in each committee. No committee transcripts were provided, but the vote totals indicate that the proposal was generally viewed positively and advanced without major opposition at the committee stage.
Contention
No specific points of contention are documented in the provided materials. Based on the bill’s subject matter, any concerns would likely center on implementation issues such as the cost of adding a new screening test, laboratory readiness, follow-up care, and whether the state should mandate screening for a condition that may require specialized confirmatory testing and treatment pathways. However, the recorded committee votes show limited opposition, suggesting that any disagreements were not substantial enough to block the bill in committee.